Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün; Jing Li; S. Shamsher Saini; Huan Yang; Premkumar Christadoss

doi:10.1016/j.jneuroim.2006.10.014

Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

Erdem Tüzün, Jing Li, S. Shamsher Saini, Huan Yang, Premkumar Christadoss

Research output: Contribution to journal › Article

23 Scopus citations

Abstract

To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

Original language	English (US)
Pages (from-to)	167-176
Number of pages	10
Journal	Journal of Neuroimmunology
Volume	182
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2006.10.014
State	Published - Jan 2007

Fingerprint

Keywords

Autoimmunity
C1q
Classical complement pathway
Myasthenia gravis

ASJC Scopus subject areas

Immunology
Clinical Neurology
Immunology and Allergy
Neurology

Cite this

Tüzün, E., Li, J., Saini, S. S., Yang, H., & Christadoss, P. (2007). Pros and cons of treating murine myasthenia gravis with anti-C1q antibody. Journal of Neuroimmunology, 182(1-2), 167-176. https://doi.org/10.1016/j.jneuroim.2006.10.014

@article{5383f48dbf1f481585af332de908fcbb,

title = "Pros and cons of treating murine myasthenia gravis with anti-C1q antibody",

abstract = "To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.",

keywords = "Autoimmunity, C1q, Classical complement pathway, Myasthenia gravis",

author = "Erdem T{\"u}z{\"u}n and Jing Li and Saini, {S. Shamsher} and Huan Yang and Premkumar Christadoss",

year = "2007",

month = jan

doi = "10.1016/j.jneuroim.2006.10.014",

language = "English (US)",

volume = "182",

pages = "167--176",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

TY - JOUR

T1 - Pros and cons of treating murine myasthenia gravis with anti-C1q antibody

AU - Tüzün, Erdem

AU - Li, Jing

AU - Saini, S. Shamsher

AU - Yang, Huan

AU - Christadoss, Premkumar

PY - 2007/1

Y1 - 2007/1

N2 - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

AB - To test the feasibility of classical complement pathway manipulation in experimental autoimmune myasthenia gravis (EAMG) treatment, C57BL/6 (B6) and RIIIS/J mice with EAMG were treated with 10 μg or 100 μg of anti-C1q Ab or isotype Ab. Treatment with 10 μg anti-C1q Ab significantly reduced the clinical severity, decreased lymph node cell IL-6 production and T cell populations. Conversely, administration of 100 μg anti-C1q Ab caused harmful side effects such as increased serum anti-acetylcholine receptor antibody, immune complex, C3 and lymph node B cell levels and kidney C3 and IgG deposits, which reduced the treatment efficacy.

KW - Autoimmunity

KW - C1q

KW - Classical complement pathway

KW - Myasthenia gravis

UR - http://www.scopus.com/inward/record.url?scp=33845884294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845884294&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2006.10.014

DO - 10.1016/j.jneuroim.2006.10.014

M3 - Article

C2 - 17137637

AN - SCOPUS:33845884294

VL - 182

SP - 167

EP - 176

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -

Access to Document

10.1016/j.jneuroim.2006.10.014